Medclair continues to grow internationally through the company's first commercial deals in both Singapore and New Zealand. The establishment on two new continents confirms the strong global demand for sustainable nitrous oxide management and proves the scalability of Medclair's partner-driven business model.
In Singapore, Medclair has, through its local partner Junnimed, received an order for a central solution for the collection and destruction of nitrous oxide at the National University Hospital (NUH). NUH is one of Singapore's leading university hospitals with a strong international position in research and clinical development. The fact that Medclair's technology is chosen by a high-profile player in such a technologically advanced region serves as a strong stamp of quality. The deal marks the company's first commercial footprint in Asia and establishes a strategically important reference facility for continued expansion in the region.
In parallel, the company has taken the step into Oceania. In New Zealand, Medclair has, through its partner Keyport Medical, received an initial order for mobile systems for MidCentral DHB. This creates a strong local platform in a market with a rapidly growing focus on the climate impact of healthcare.
These establishments are a testament to Medclair's focused growth strategy: entering into strong local partnerships to quickly establish reference facilities, which then serve as door openers for broader regional upscaling.